MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

02 Feb 2024 Evaluate
Revenue reduced marginally to stand at Rs. 1752.00 millions during the quarter ended December 2023. The figure stood at Rs. 1828.00 millions during the year-ago period.The Net Loss for the quarter ended December 2023 is Rs. -24.00 millions as compared to Net Loss of Rs. -59.00 millions of corresponding quarter ended December 2022Operating profit surged to 183.00 millions from the corresponding previous quarter of 59.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 1752.00 1828.00 -4.16 5789.00 6103.00 -5.15 8101.20 7257.30 11.63
Other Income 190.00 78.00 143.59 533.00 1242.00 -57.09 1378.90 1261.60 9.30
PBIDT 183.00 59.00 210.17 576.00 1252.00 -53.99 1411.10 1326.20 6.40
Interest 83.00 55.00 50.91 218.00 128.00 70.31 185.20 109.90 68.52
PBDT 100.00 4.00 2400.00 358.00 1124.00 -68.15 1225.90 1216.30 0.79
Depreciation 123.00 116.00 6.03 356.00 319.00 11.60 432.50 369.10 17.18
PBT -23.00 -112.00 -79.46 2.00 805.00 -99.75 793.40 847.20 -6.35
TAX 1.00 -53.00 -101.89 11.00 -2.00 -650.00 294.60 42.30 596.45
Deferred Tax 5.00 -53.00 -109.43 11.00 -146.00 -107.53 156.40 -100.50 -255.62
PAT -24.00 -59.00 -59.32 -9.00 807.00 -101.12 498.80 804.90 -38.03
Equity 159.00 159.00 0.00 159.00 159.00 0.00 159.30 159.30 0.00
PBIDTM(%) 10.45 3.23 223.62 9.95 20.51 -51.50 17.42 18.27 -4.68
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..